

Edgar Filing: CEL SCI CORP - Form NT 10-K

CEL SCI CORP  
Form NT 10-K  
December 28, 2004

U.S. SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SEC File Number 0-11503  
CUSIP Number 150-837-409

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One):

Form 10-K  Form 20-F  Form 11-K  Form 10-Q  Form N-SAR

For Period Ended: September 30, 2004  
-----

Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.  
-----

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: N/A  
-----

Part I - Registrant Information  
-----

Full Name of Registrant: Cel-Sci Corporation

Former Name if Applicable: N/A

Address of Principal Executive Office (Street and Number)

8229 Boone Blvd. #802

City, State and Zip Code

Vienna, VA 22182  
-----

Part II - Rules 12b-25(b) and (c)  
-----

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  
(Check box if appropriate)

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

Edgar Filing: CEL SCI CORP - Form NT 10-K

[X] (b) The subject annual report, semi-annual report, or transition report or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Part III - Narrative

State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, or N-SAR, or the transition report or portion thereof could not be filed within the prescribed time period.

The Company has been working on an application to the FDA for Phase III clinical trials. The materials required as part of the application took a considerable amount of time to assemble. As a result, additional time is needed to file its 10-K report for the year ended September 30, 2004.

Part IV - Other Information

(1) Name and telephone number of person to contact in regard to this notification

William T. Hart (303) 839-0061
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) been filed? If answer is no, identify report(s). [X] Yes [ ] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [X] No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Cel-Sci Corporation
(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 23, 2004 By /s/ Geert R. Kersten
Geert R. Kersten,

Edgar Filing: CEL SCI CORP - Form NT 10-K

Chief Executive Officer

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).